NCL News Archive

Wednesday, May 15, 2019

Identifying the Risk of Infusion Reactions

The NCL has just launched a new Technical Service to assess the potential for infusion reactions. Systemic administration of nanomedicines (and other therapies) have the potential to cause infusion reactions in patients, which often delays or halts their clinical translation. These reactions can manifest as fevers, chills, rigors, rashes, chest or back pain, or difficulty breathing, and, in... View Post


Tuesday, April 9, 2019

NANOBIOTIX Announces First Ever Radioenhancer to Receive European Market Approval

Former NCL Collaborator NANOBIOTIX recently announced European market approval for their formulation Hensify® (NBTXR3). Per the press release:

Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma Hensify®--a first-in-class radioenhancer--offers cancer patients an... View Post


Thursday, April 4, 2019

New Mechanistic Immunotoxicology Protocols

NCL's Immunology team has put together a series of new protocols which probe various immunotoxicology aspects of nanomedicines. The 7 new protocols have been published on the NCL Assay Cascade Protocols webpage and are available for download. They include:

 

ITA-26: Detection of Intracellular Complement Activation in Human T Lymphocytes

The complement... View Post


Tuesday, March 5, 2019

CRS Nanomedicine and Nanoscale Delivery Webinar

The Controlled Release Society’s (CRS) Nanomedicine and Nanoscale Delivery Focus Group will host their first webinar in March, given by NCL Director, Scott McNeil. This webinar will highlight the unique challenges of nanomedicine development, including the complex characterization requirements for these formulations and the hurdles of regulatory review. Having characterized more than 400... View Post


Tuesday, March 5, 2019

December 2018 Awardees Announced

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Friday, February 1, 2019

Position Available: Research Associate, Physicochemical Characterization

The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Research Associate to join... View Post


Friday, February 1, 2019

Position Available: Scientist, Physicochemical Characterization

The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Scientist to join our... View Post


Friday, February 1, 2019

JoVE Publication on LAL Assay

Endotoxin testing has been one of the most commonly requested needs among nanotech researchers applying to the NCL. Dr. Marina Dobrovolskaia, Sr. Principal Scientist, has spent more than a decade studying the intricacies of endotoxin detection in nanoformulations. Much of her work has focused on assessing the pros and cons of the various detection methods and determining ways to overcome... View Post


Friday, October 26, 2018

Licensing Opportunity: Novel Scavenger Receptor A1-Targeted Macromolecular Prodrug Platform

Investigators at the NCL have developed a drug delivery platform that targets scavenger receptor A1, a receptor highly expressed in macrophages, monocytes, mast cells, and dendritic cells (myeloid lineages), as well as endothelial cells. The platform is based on the anionic polymer poly(L-lysine succinylated), which contains side chains with pendant carboxylic acids that allow conjugation of... View Post


Thursday, October 18, 2018

Changes to NCL Application Due Dates for 2019

Beginning in 2019 the NCL will accept applications twice per year, a change from previous years in which applications were accepted quarterly. The due dates for applications will be the first business days of March and September.

For those of you still hoping to apply this year, we are still accepting December applications this year, with the due date... View Post


Pages